MarketPulse
V

$VRDN

4 articles found
0 positive
3 negative
1 neutral
The Motley FoolThe Motley Fool··Andy Gould

Kopp Family Office Dumps $3.5M Viridian Stake as Biotech Stock Tanks 50%

Kopp Family Office exits $3.5M Viridian stake as stock plummets 50% following disappointing Phase 3 data and Amgen's superior competing results.
AMGNVEAVRDNAGGFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson Fistel, Pllp

Law Firm Investigates J.Jill for Potential Securities Fraud Over Holiday Performance Disclosure

Law firm Johnson Fistel investigates J.Jill for potential securities fraud following March 2026 earnings disclosure of poor holiday performance and customer migration toward discounts.
VRDNRHJILLclass action lawsuitinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Johnson Fistel, Pllp

Johnson Fistel Investigates Viridian Therapeutics Over Phase 3 Trial Disclosure

Johnson Fistel investigates Viridian Therapeutics for potential securities law violations related to Phase 3 REVEAL-1 trial disclosures, offering shareholders potential loss recovery options.
VRDNBAKTATTsecurities fraudinvestor losses
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Fund Liquidates $69M Viridian Position Despite 75% Annual Rally

Commodore Capital liquidates its entire $69M Viridian position despite the stock's 75% annual rally, signaling strategic reallocation ahead of anticipated FDA decisions.
VRDNALKSTYRAbiotech portfolio exitposition liquidation